Kalaris Therapeutics appoints Liisa Bayko as CFO

Seeking Alpha··Read original
2▲0 ▼0Impact / 5
Summary · why it matters

Kalaris Therapeutics has appointed Liisa Bayko as chief financial officer. Bayko brings more than two decades of experience in biotechnology finance, strategy, and capital markets, most recently serving as managing director and senior biotechnology analyst at Evercore ISI. Shares of Kalaris Therapeutics fell 5.25 percent to $4.15 in pre-market trading.

Impact on assets 1

Health Care▲ · 1 stocks
Kalaris Therapeutics, Inc.
KLRS
± MixedCapitalrelevance

Appointment of a new CFO with capital markets experience, but stock fell 5.25% in pre-market, indicating mixed market reaction.

© 2026 MarketIVNews